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1. Introduction  
Stereotactic body radiation therapy (SBRT) is a radiotherapy technique that utilizes 
precise targeting to deliver high doses of tumoricidal radiation in the course of a small 
number of treatment sessions. SBRT is used to treat a variety of primary and metastatic 
tumours of the lung, liver, pancreas, kidney, spine and prostate. These treatments are 
already standard for medically inoperable early lung cancer and indications are evolving 
for other disease sites.  
In SBRT of liver lesions (Dawood et al., 2009; Lo et al., 2010), tumour-targeting accuracy is 
crucial given the radiosensitive nature of the liver, frequent proximity of the tumour to the 
small bowel and significant movement of the liver with breathing. Reduction of normal 
tissue irradiation requires the radiation to be image-guided (as opposed to relying on skin 
marks or body casts). This image-guidance is typically accomplished through visualization 
of a surrogate to the tumour. The surrogate can be the whole liver, the diaphragm or an 
implanted marker (Wunderink et al., 2010). 
Implanted markers have the advantage of being visible on planar x-ray images and 
fluoroscopy loops. If large enough, they can also be seen on images produced with the 
treatment beam. The details of the implementation of fiducial imaging vary with different 
radiotherapy devices but typically images of the fiducials are correlated to the position of 
the chest wall at different points in the breathing cycles. This gives the user knowledge of 
the displacement of the tumour (assumed to be at a fixed distance from the fiducials). One 
can then choose to turn on the beam in a specific phase of the breathing cycle or have the 
radiation delivery device track the movement of the tumour. 
As an example, the Cyberknife system acquires up to 15 pairs of stereoscopic x-rays just 
before treatment. Fiducials are automatically detected by the system’s image analysis 
software. The 3D position of the fiducials is then correlated to the position of chest wall as 
recorded by the movement of 3 lights on the patient’s chest. The robot on which the 
radiation source is mounted can then use the model correlating chest wall motion and 
fiducial motion to mimic the movement of the tumour while the patient breathes (Figure 1). 
In this process, there is continuous monitoring (via cameras) of the chest wall but only 
intermittently imaging of the fiducials with stereoscopic x-rays. These additional x-rays are 
used to verify and update the correlation model. 
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Fig. 1. Cyberknife radiosurgery device. X-ray tubes (A) are used to produce stereoscopic 
images recorded digitally (B) and correlated to the movement of lights on the patient’s chest 
(C) which are monitored by two cameras (D). The model correlating the position of the chest 
wall to the position of the fiducials seen on the x-ray images is used to guide the miniature 
linear accelerator at the head of the robot (E). 
2. Percutaneous fiducial implantation technique 
Fiducials are inserted using image-guidance (Sotiropoulou et al., 2010). Before the 
procedure, appropriate laboratory parameters are obtained and reviewed within an 
acceptable time frame, these include a complete blood count and prothrombin time with 
international normalized ratio. Patients with previously documented abnormalities in 
laboratory tests may require these to be repeated closer to the time of the procedure. Platelet 
transfusions are considered for platelet levels of less than 60,000/mL. Antiplatelet 
medications should be discontinued 7 days before the fiducial implantation; warfarin is 
generally discontinued 5 days before insertion, and heparin and related products 
discontinued 12-24 hrs prior to the procedure. Barring complications, these treatments can 
be restarted 24-48 hours following the procedure. 
Imaging of the target lesion is reviewed with the radiation oncologist. This enables proper 
planning of the procedure, selection of the appropriate equipment (depending if a biopsy is 
required or not) and lesion(s) (it is possible that only selected lesions will be targeted for 
radiotherapy, and therefore for fiducial implantation).  
The fiducial insertion is typically performed on an outpatient basis. The choice of imaging 
modality will depend on availability and operator preference. Most radiologists are 
comfortable with ultrasound or CT guidance. Although each modality has its advantages, 
certain situations may require a specific type of imaging. Typically CT is preferred for 
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fiducial insertion. Most patients are poor candidates for ultrasound-guided procedure 
because of body habitus, previous liver surgery and/or the presence of multiple lesions. CT 
also allows a pre-implant scan that can be acquired with contrast. This allows a better 
mapping of the target lesion and its neighbouring vascular structures, hopefully resulting in 
better fiducial placement with reduced risk of migration.  This CT can also be used for 
treatment planning if the fiducials subsequently cause significant artefact.  
Needle selection is based on the type of fiducial to be use, the number of fiducials to be 
placed and if a biopsy is required or not. A coaxial 19G needle is useful to perform a small-
gauge core biopsy (18G), have enough tissue for histological analysis, and also allows for 
placement of our cylindrical gold fiducials. 
 
 
Fig. 2. A) A 22G needle is placed with a low radiation dose CT scan to place a Nester 
platinum coil. This case has a 6 cm lesion and 4 coils were placed at different levels (B, C, D). 
With current radiotherapy systems, treatment can – if necessary – proceed with a single 
marker. The disadvantages of using a single marker are that movement of the marker within 
the liver will be difficult to detect and rotation of the target will not be reflected by the 
position of the marker. Geometrically, a minimum of 3 markers are required to assess 
rotations (as long as the fiducials are not all in a straight line). Extra markers also allow 
detection of migration (a constant relationship between the markers will reflect stability in 
their position). When there are too many markers or they are too close together (the 
Cyberknife system, as an example, suggests a minimum spacing of 2cm) this may lead to 
confusion at the time of treatment. The markers need not be within the lesion, as long as 
they will move in synchrony with the tumour. For example, markers can be implanted 
below a lesion high under the dome of the diaphragm in order to avoid the risk of 
pneumothorax. For small lesions, two markers placed at different sites but through the same 
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puncture may be sufficient; however, for bigger lesions, 3-4 markers may be preferred and 
the procedure may require multiple punctures.  
At the end of the implant, a final scout imaging will confirm intra-hepatic fiducial placement. 
2.1 Types of fiducial markers 
Fiducials are typically made of a biologically inert metal with a high atomic number. These 
can be designed specifically for radiotherapy, repurposed devices or simple non-commercial 
materials.  Several issues will be considered in choosing a marker. These include price, 
convenience, availability as well as the specific imaging system used for radiotherapy 
guidance. 
Modern radiotherapy equipment will most often be purchased with an integrated kilovoltage 
imaging source dedicated to image-guidance. These systems should be able to easily resolve 
small gold markers with a diameter of 0.5mm (or less) but will be influenced by body habitus 
and overlying structures. To be visible with a megavoltage radiotherapy beam, markers will 
need to be thicker (this may mean 0.75-1.1mm diameter for gold) or longer (in the case of a 
marker which will coil up into a dense mass as it exits the needle). Images thus obtained as the 
treatment beam traverses the patient can be an excellent quality assurance tool.  
 
Type of fiducial Material Diameter Shape 
Needle 
gauge 
Provider 
Plain / Non-
commercial 
     
Spheres Gold 2.0 mm spherical ≥12 ga varied 
Cylinder / wire Gold varied cylindrical varied varied 
Repurposed      
Embolization 
coils 
Platinum 0.889 loose coil 22 ga Cook Medical 
Commercial      
Visicoil™ Gold 0.35-1.1mm
tight linear coil 
 
17-19 ga Core Oncology 
Best Gold 
Markers 
Gold 0.8-1.2mm 
cylindrical, available with 
absorbable spacer 
17-18 ga Best Medical 
Cybermark™ / 
Align™ 
Gold 0.8-1.2mm Knurled solid cylinder 17-18 ga 
Civco medical 
solutions 
Coupled™ Gold 0.8-1mm 
two 3mm cylinders with 
absorbable spacer 
17-18 ga 
Civco medical 
solutions 
FlexiMarc™ Gold 0-9-1.2mm 
gold nodes along thin gold 
wire 
17-18 ga 
Civco medical 
solutions 
FlexiCoil™ Gold 0-9-1.2mm tight coil with solid ends 17-18 ga 
Civco medical 
solutions 
X-Mark™ / X-
Mark Ultra™ 
Gold 
0.85-
1.15mm 
multiple short bands along 
gold wire 
17-18 ga 
IZI Medical 
Products 
Gold Anchor™ Gold 0.28mm bendable notched wire 22-25 ga 
Naslund 
Medical AB 
/ Radiadyne 
AnchorMarke® Gold n/a 
cylinder encapsulated in 
bioabsorbable polymer 
n/a BrachySciences 
BeamMarks® 
Nickel 
titanium
1-1.2mm extruded star shape n/a Beampoint 
Table 1. Radiotherapy fiducials 
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The simplest markers are sterile sections of gold wire or gold spheres. Repurposed markers 
can include embolization coils designed for intravascular use. We have had good experience 
with these platinum coils as they can be placed with fine needles, are stable in the liver and 
are easily visualized with radiotherapy imaging. A disadvantage of these coils is that they 
can sometimes fail to bunch up into a tight mass — when this happens, they don’t offer as 
precise a reference as a small solid piece of gold. Dedicated markers tend to have been 
designed to increase convenience and limit migration. Markers can thus be provided pre-
loaded in needles or carriers. The markers can have an irregular surface or a bendable 
structure to “hook” into the liver. Tissue absorbable material between markers can be used 
to preserve marker spacing and reduce migration within the needle track. A common 
commercial radiotherapy fiducial (Visicoil, Core Oncology, Santa Barbara, CA) has a linear 
shape. As these markers can be 2-3 cm long, both ends of a single marker may be 
informative in resolving possible target rotation. 
 
 
Fig. 3. Examples of a repurposed (platinum embolization coil on the left) and non-
commercial (section of gold wire on the right) fiducial 
3. Risks of percutaneous fiducial implantation 
Fiducial placement is the source of several inconveniences. It leads to a delay in treatment —
 even when appointments are readily available, many clinicians will impose up to a one 
week delay from fiducial placement to treatment planning in order to allow the markers to 
“settle”. The procedure is associated with additional costs and the fiducials can create 
significant imaging artefacts on CT. In addition, the percuteneous procedure has a variety of 
risks. Minor complications have been reported in 17.3% and major complications in 5% of 
cases (Kothary et al., 2009). There are generic risks that come with introducing any needle 
into the liver: pain, pneumothorax, hemothorax, perforation of non target organs (the 
gallbladder being the most common), bile peritonitis, infection, hemobilia, neuralgia and 
tumour seeding. For most of these events, the biopsy literature serves as a basis of a risk 
estimate. Specific to fiducial placement is the risk of migration of the marker. 
3.1 Pain 
Pain is the most common complication on any percutaneous procedure. Up to 84% of 
patients will have at least mild discomfort. When present, pain can usually be managed 
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with small amounts of narcotics (Cardella et al., 2003). Is important to recognize and 
evaluate any moderate to severe pain, which could be related with bleeding, gallbladder or 
biliary puncture. When pain is severe enough to require hospitalization, radiological 
evaluation is warranted 
3.2 Fiducial migration 
Fiducial migration is a twofold problem, first because of the risk of tumour mistargeting if 
unrecognized migration occurs within the organ of interest, and second because of potential 
toxicity from the marker escaping through the hepatic veins. 
3.2.1 Gross fiducial migration 
Fiducials and radioactive seeds are commonly placed in the prostate. There is ample 
literature describing migration of these to the lung (without any serious consequence). In 
placing gold markers for pulmonary radiation, migration into the pleural cavity, pulmonary 
veins or bronchial tree will sporadically occur. For the liver, the available literature is more 
limited, with hepatic veins representing the potential route of fiducial migration (no cases of 
biliary tree migration have been reported).  
In a series of 21 patients implanted with 2 mm gold spheres, one of the fiducials migrated 
through the inferior vena cava to a small vein at the hip where it remained lodged without 
apparent clinical consequence (Shirato et al., 2003). In a series from Stanford University 
Medical Center, 33 patients underwent CT-guided placement of 0.8 mm by 5 mm hepatic 
fiducials. In these cases there was no gross marker migration and one patient experienced a 
small hemorrhagic pleural effusion (Kothary et al., 2009). 
 
 
Fig. 4. Platinum coil lodged at the junction of the inferior vena cava and right atrium after 
migration from the liver. 
www.intechopen.com
 
Percutaneous Liver Fiducial Implants: Techniques, Materials and Complications 
 
113 
In our own experience, we had a case of cardiac migration of a liver fiducial (Hennessey et 
al., 2009). This occurred in an 81 year old patient planned for SBRT in the context of 
oligometastatic gastric cancer. For image-guidance, Nester embolization coils (Cook Medical 
Inc., Bloomington, Indiana) were planned to be implanted under CT guidance. Prior to the 
placement of each coil the location of the tip of the delivery needle was confirmed by CT 
imaging. During the procedure, the third coil unexpectedly migrated through the hepatic 
vein to the inferior vena cava and lodged at the vena cava/right atrial junction. The patient 
remained asymptomatic. He was immediately referred to angiography for extraction of the 
coil. Using fluoroscopic guidance, an EN Snare Retrieval System (Hatch Medical L.L.C., 
Snellville, GA, USA) was introduced through a jugular catheter, successfully grasped the 
coil and was removed. The patient was kept overnight for observation and no immediate or 
delayed complications were encountered due to the migration or retrieval of the coil. He 
subsequently went on to be treated using the remaining fiducials 
3.2.2 Intra-hepatic fiducial migration 
Migration of fiducials within the targeted organ has been described. Most published work 
concerns prostate radiotherapy with studies looking at the relative position of 3-4 prostate 
markers as a surrogate to migration (Sommerkamp et al., 1988). In limited experience with 
hepatic fiducials, intra-organ migration appears minimal — in the order of 2-3mm 
(Sommerkamp et al., 1988; Kitamura et al., 2002). However, quantification of movement 
within the liver is limited by the frequent lack of precise landmarks within this large, 
deformable organ. To deal with this issue, clinicians have relied on treatment margins, 
repeated 3D imaging and/or implantation of redundant fiducials. 
3.3 Bleeding 
The most important complication of liver puncture is bleeding, that can be severe when it 
occurs intraperitoneally. The clinical signs include changes in vital signs, imaging evidence 
of intraperitoneal bleeding, and subcutaneous hematoma. In this case, the patient requires 
hospitalization with possible transfusion, radiological intervention or surgery. Such 
bleeding has been estimated to occur in between 1:25,000 to 1:10,000 procedures after an 
intercostal percutaneous approach. Severe bleeding is evident within 2-4 hrs, but late 
haemorrhage can occur even up to one week after the procedure. Less severe bleeding, 
defined as that sufficient to cause pain or decreased blood pressure / tachycardia, but not 
requiring transfusion or intervention, occurs in approximately 1 in 500 procedures (Cardella 
et al., 2003; Seeff et al., 2010). 
Non-symptomatic bleeding, detectable by ultrasonography may occur in 20% of patients.  
3.4 Pneumothorax 
Pneumothorax is critical to recognize immediately after the procedure, because it can lead to 
immediate catastrophic outcomes. This is the most frequent complication after lung 
implantation, although only 14% of these require a chest tube to resolve (Sotiropoulou et al., 
2010). Pneumothorax is less frequent on liver fiducal placements. An advantage of CT 
guidance is the easy diagnosis of pneumothorax with immediate treatment. 
3.5 Tumour seeding 
Although there are no reports of malignant seeding after fiducial placement, it is possible 
that this can occur at a similar rate than for other percutaneous diagnostic and therapeutic 
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procedures in patients with HCC. For example, in a meta-analysis the median risk of 
seeding was 2.3% for the biopsy group and less than 1% for RFA with or without biopsy 
(Stigliano et al., 2007). 
 
 
Fig. 5. Tumour seeding following percutaneous biopsy 
4. Alternatives to percutaneous fiducial implantation 
Fiducials are for now often a necessary evil. As radiotherapy image-guidance develops, the 
use of fiducials will likely decrease. This will happen faster in the lung, where the tumours 
can be more easily visualized on 2D and non-contrast 3D imaging. Alternatives to 
percutaneous fiducial placement have developed in the chest mainly in an attempt to reduce 
the risk of pneumothorax. In the abdomen, the need for alternatives has not been as strongly 
felt without common serious complications.  
4.1 Endoscopic ultrasound (EUS) fiducial placement 
Endoscopic ultrasound (EUS), has the advantage of proximity to structures of the 
mediastinum and retroperitoneum that are otherwise not easily accessible by percutaneous 
approaches (Varadarajulu et al., 2010). Initially, the EUS technique required the use of a 19G 
FNA needle to deliver the fiducial, but because of the size and stiffness of the needle, the 
accurate placement of fiducials was compromised. The introduction of new smaller fiducial 
markers that can fit on a 22G needle now allows optimal placement in a variety of locations. 
It is minimally invasive and allows easy access to structures around the GI track. More 
frequently suggested for pancreatic lesions, it may also be used for retroperitoneal lymph 
nodes, the left adrenal gland, and the left hepatic lobe, including the caudate. The fiducials 
are liberated through the stomach or duodenum, commonly with prophylactic antibiotics 
(Ammar et al., 2010; DiMaio et al., 2010). 
Reported success rates of EUS-guided fiducial placement are 85 to 100% with minimal 
complications and no migration. Failure to place a fiducial in the desired location was due to 
either anatomic considerations or limitations of the equipment when a 19G needle was used. 
The technical success using a 22G needle is reported at 97% because this type of needle does 
not produce the same endoscope rigidity as the 19G needle. 
Despite these reports, the use of EUS for liver fiducial placement remains anecdotal and 
restricted to the left lobe. 
4.2 Non fiducial based image-guidance 
Modern radiotherapy devices often have the capability to acquire volumetric imaging at the 
time of treatment. These “cone-beam” CT scans typically take 30-60 seconds to acquire and 
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thus suffer from breathing artefacts. As the technology advances, it is becoming possible to 
sort the images acquired during a rotation into phases of a 4D CT scan. It is also possible, in 
some cases, to use multiple breath holds to acquire a 3D image at a fixed point in the 
respiratory cycle. The volumetric image is then used to position the patient for treatment 
(Case et al., 2009). Because the tumour will typically not be visible, the entire liver will be 
used as a surrogate. Although they avoid fiducial placement, these techniques have the 
disadvantage of not allowing monitoring of the tumour position during treatment.  
4.3 Endovascular fiducial placement 
In specific situations such as severe ascites, a known or suspected hemostatic defect or 
morbid obesity, patients can undergo intrahepatic artery coils implant.  The Nester type 
coils (Cook, Inc; Bloomington , IN) may have a special role because its platinum structure 
that is radiopaque and easy to visualize during the radiotherapy. They can be liberated with 
a 0.035 inch catheter; microcatheters can also be used for a more selective coil placement. 
When possible, two or three different tumour vessels should be embolized and at the most 
distal position possible. The intra-arterial coil placement has the benefit of low risk of 
migration, and the proximity with the target lesion; it has the disadvantage of blocking an 
artery that could be used for further chemoembolisation. 
Intravenous fiducial placement is described for lung tumour. There are no cases, to our 
knowledge, of this type of procedures for liver lesions, which could have a high risk of 
migration. 
5. Conclusion 
Interventional radiologist and radiation oncologist often collaborate in the implantation of 
radio-opaque markers for the targeting of focused radiation. Although this percutaneous 
fiducials placement is a useful and generally safe procedure, it carries a variety of small risks 
of which radiologists, radiation oncologists and patients should be aware.  
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